Orgenesis Inc (NASDAQ:ORGS) has announced the launch of its BioShield Program, which is designed to use neutralizing human antibodies as a possible rapid defense and to potentially mitigate the spread of viruses such as the coronavirus that causes the COVID-19 disease.
The goal of the BioShield Program is to increase the level of preparedness to fight against emerging outbreaks and help avoid a global pandemic, the company said in a statement Wednesday.
Orgenesis said it plans to leverage its POCare anti-viral technologies as part of the development efforts of the BioShield Program, including exploration of alternative and breakthrough processes to induce neutralizing antibody discovery and validation against targeted pathogens.
READ: Orgenesis to conduct clinical study of tumor-infiltrating lymphocytes with Israeli public hospital
The BioShield Program is designed to combine different technologies in preclinical stage to induce a response of the immune system within selected animal models, which could potentially speed the discovery of neutralizing antibodies.
Orgenesis’ cell-based vaccine approach, which utilizes irradiated permissive cells that have the ability to activate an endogenous immune response, is a component of the BioShield Program.
When Orgenesis’ cell-based vaccine is infused into a humanized mouse model, these activated cells are designed to induce generation of neutralizing antibodies.
If the company is successful in validating these technologies, Orgenesis said it believes this could represent a platform for the potential rapid identification and isolation of human neutralizing antibodies to be tested as antiviral therapies against current and future emerging outbreaks.
Given the health emergency and the need for preparedness against future pathogen outbreaks, Orgenesis said it has committed resources to immediately pursue development of the BioShield Program.
“When faced with new infectious diseases, there is a need for a rapid, affordable and effective solution to shut down the pathogen outbreak,” said CEO Vered Caplan.
“By specifically leveraging Orgenesis’ POCare anti-viral platform, our objective with the BioShield Program is to provide a rapid and affordable solution to contain the spread of a viral pathogen or new emerging outbreaks.”
Orgenesis, based in Germantown, Maryland, is focused on accelerating the commercialization of transforming the delivery of cell and gene therapies while also lowering costs.
Contact the author: [email protected]
Follow him on Twitter @PatrickMGraham
Story by ProactiveInvestors
Please Help Support BeforeitsNews by trying our Natural Health Products below!
Order by Phone at 888-809-8385 or online at https://mitocopper.com
Order by Phone at 888-809-8385 or online at https://www.herbanomic.com
Get our Free Ebook, "Suppressed Health Secrets" with Natural Cures THEY don't want you to know!
Humic & Fulvic Trace Minerals Complex - Nature's most important supplement! Vivid Dreams again!
Ultimate Clinical Potency Curcumin - Natural pain relief, reduce inflammation and so much more.
pathogens and gives you more
energy. (See Blood Video)
Oxy Powder - Natural Colon Cleanser! Cleans out toxic buildup with oxygen!
Organic Hemp Extract (CBD) - Full Spectrum high CBD (3300mg) hemp extract eases stiff joints, relieves stress and more!
Nascent Iodine - Promotes detoxification, mental focus and thyroid health.
Smart Meter Cover - Reduces Smart Meter radiation by 96%! (See Video)
Immusist Beverage Concentrate - Proprietary blend, formulated to reduce inflammation while hydrating and oxygenating the cells.